60 Degrees Pharmaceuticals, Inc. reported a 223% increase in net product revenue for Q3 2025, reaching $438 thousand. However, gross profit decreased to $(100) thousand due to a one-time inventory write-off. Operating expenses rose to $2.32 million, with a net loss of $2.44 million for the quarter. The company also announced strategic partnerships for future drug development, including a study with Tulane University and the Icahn School of Medicine at Mount Sinai. Additionally, 60 Degrees Pharmaceuticals plans to seek FDA approval for new canine babesiosis treatment.

In other news, the total addressable market for babesiosis treatment was determined to be up to $1.1 billion through 2035 after a comprehensive survey. The company is working on a Phase II clinical study for chronic babesiosis treatment. 60 Degrees Pharmaceuticals specializes in developing medicines for vector-borne diseases and was founded in 2010. They have collaborated with research organizations in the U.S., Australia, and Singapore. The company is headquartered in Washington D.C., with a subsidiary in Australia. Investors are urged to review SEC filings for more information on potential risks.

Read more at GlobeNewswire: 60 Degrees Pharmaceuticals Announces Third Quarter 2025